Last reviewed · How we verify
NCT07044466: OUD
Social Functioning in Opioid Use Disorder
NA trial testing CBT4CBT-Buprenorphine in Opioid Use Disorder in 230 participants. Currently enrolling.
31 August 2029
Quick facts
| Lead sponsor | Medical University of South Carolina |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 230 |
| Start date | 25 April 2026 |
| Primary completion | 31 August 2029 |
| Estimated completion | 31 August 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CBT4CBT-Buprenorphine
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
Medical University of South Carolina
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Problems with social functioning are core to opioid use disorder (OUD), though specific, modifiable social functioning targets and how they relate to OUD treatment outcomes are poorly understood. This study will utilize both data from both patients with OUD and their concerned significant other (CSO) to examine associations between specific social functioning metrics and OUD treatment outcomes. Findings from this study will inform future precision-medicine approaches for people with OUD, a population in significant need of enhanced treatment approaches to combat opioid morbidity and mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07044466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CBT4CBT-Buprenorphine
Trials testing the same drug.
- NCT03580902 — CBT4CBT for Office Based Buprenorphine · Phase 1, PHASE2 · completed
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
- NCT07342504 — Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist · NA · recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
- NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
- NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
- NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07044466 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07044466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing